FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | _ OWNERSHIP |
|------------------|-------------------|---------------|-------------|

| OMB APPROVAL | | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average t | ourden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | | | | | | . 50. | iipaiiy Act | | | _ | | | | | | |
|---|--|--|---|--------------------------------|--|---|--|------|--|---|---|-----------------|---|---|---|---|--|---------------------------------------|------------|--|
| Name and Address of Reporting Person* SOUTHWELL DAVID P | | | | | | 2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT] | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
| SOUTHWELL DAVID P | | | | <u> </u> | | | | | | | | X | Directo | r | | 10% Ov | vner | | | |
| (Last) | ` | * | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/05/2023 | | | | | | 1 | Officer below) | (give title | | Other (s below) | specify | | | |
| C/O PTC THERAPEUTICS, INC. | | | | | | | | | | | | | | | | | | | | |
| 100 CORPORATE COURT | | | 4.16 | | | | f O | =:11 | (A. 4 4 - /D - | C. Individual or Joint/Crown Filing (Chook Assistable | | | | | | | | | | |
| (Ctroot) | | | | | 4. 11 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) SOUTH | | | | | | | | | | | | | | | X Form filed by One Reporting Person | | | | | |
| PLAINF | IELD N | J | 07080 | 080 | | | | | | | | | | | Form fi Person | filed by More than One Reporting n | | | rting | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transc Date (Month/D | | | | | Execution Date, | | 3. Transaction Code (Instr. 8) 4. Securitic Disposed (5) | | | | | | es Fo ally (D) Following (I) | | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | | Code | v | Amount | (A) (D) | or F | Price | Reported Transact (Instr. 3 a | tion(s) | | | (Instr. 4) | |
| Common Stock 01/0 | | | 01/05 | /2023 A 4,000 ⁽¹⁾ A | | \$ <mark>0</mark> | 10,500 | | | D | | | | | | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Da if any (Month/Day/ | ate, T | 4. Transaction Code (Instr 8) | | n of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | urity | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | e S Illy | Ownership Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) | | |
| | | | | c | code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | or Nu of | mber ares | | | | | | |
| Stock Option (Right to Buy) | \$39.42 | 01/05/2023 | | | A | | 10,000 | | (2) | 0 | 1/04/2033 | Common Stock | 10 | ,000 | \$0 | 10,000 | 0 | D | | |

Explanation of Responses:

- 1. Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.
- 2. This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023.

/s/ Avraham S. Adler, Attorney-01/09/2023 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.